Comparing Two Standard Bevacizumab Doses with Chemotherapy for Platinum-Resistant Ovarian Cancer

What this Trial Is About

Researchers are evaluating two standard doses of the anti-cancer drug bevacizumab combined with chemotherapy in patients with epithelial ovarian cancer that is resistant to platinum-based chemotherapy. This pragmatic, randomized trial aims to compare a lower dose 7.5 mgkg versus a higher dose 15 mgkg of bevacizumab to see if the lower dose is not worse than the higher dose in controlling cancer progression while potentially reducing side effects and treatment costs. Participants will be randomly assigned to receive either 7.5 mgkg or 15 mgkg doses of bevacizumab every three weeks, combined with chemotherapy. The treatment duration will be determined by the treating clinicians based on standard care. The study compares progression-free survival, side effects, quality of life, and drug cost savings between the two dosing groups. During the study, participants will undergo regular CT scans to monitor disease progression, and side effects will be tracked. Quality of life assessments will be conducted during treatment and four weeks after stopping treatment. Researchers will follow participants for up to four years to assess progression-free survival and overall survival, along with treatment response duration and adverse events. Safety and treatment outcomes will be carefully monitored throughout the trial.

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer